DOI: 10.1128/AAC.04616-14
Article Figures & Data
Tables
- TABLE 1
Antimicrobial activity and MIC distribution for telavancin against a contemporary (2011 to 2013) U.S. collection of S. aureus clinical isolates using a recently approved and revised susceptibility testing method
S. aureus categorya (no. of isolates tested) MIC (μg/ml) No. (cumulative %) of isolates inhibited by telavancin at indicated MIC (μg/ml)b 50% 90% ≤0.015 0.03 0.06 0.12 All (9,610) 0.03 0.06 364 (3.8) 6,210 (68.4) 3,012 (99.8) 24 (100.0) MSSA (4,959) 0.03 0.06 242 (4.9) 3,272 (70.9) 1,437 (99.8) 8 (100.0) MRSA (4,651) 0.03 0.06 122 (2.6) 2,938 (65.8) 1,575 (99.7) 16 (100.0) Vancomycin MIC, ≤1 μg/ml (4,561) 0.03 0.06 119 (2.6) 2,930 (66.8) 1,502 (99.8) 10 (100.0) Vancomycin MIC, 2–4 μg/ml (90) 0.06 0.06 3 (3.3) 8 (12.2) 73 (93.3) 6 (100.0) Daptomycin MIC, ≤0.5 μg/ml (4,607) 0.03 0.06 122 (2.6) 2,928 (66.2) 1,545 (99.7) 12 (100.0) Daptomycin MIC, 1–2 μg/ml (43) 0.06 0.06 0 (0.0) 9 (20.9) 30 (90.7) 4 (100.0) MDR (1,371) 0.03 0.06 37 (2.7) 749 (57.3) 574 (99.2) 11 (100.0) Non-MDR (3,280) 0.03 0.06 85 (2.6) 2,189 (69.3) 1,001 (99.8) 5 (100.0) - TABLE 2
Antimicrobial activity of telavancin and comparator agents tested against a contemporary (2011 to 2013) U.S. collection of clinical isolates using a recently approved and revised susceptibility testing method
Organism categorya (no. tested) and antimicrobial agent MIC (μg/ml) % susceptible/% intermediate/% resistantb 50% 90% FDA CLSI EUCAST MSSA (4,959) Telavancin 0.03 0.06 100.0/-c/- -/-/- -/-/- Vancomycin 1 1 100.0/0.0/0.0 100.0/0.0/0.0 Daptomycin 0.25 0.5 >99.9/-/- >99.9/0.0/<0.1 Linezolid 1 1 >99.9/0.0/<0.1 >99.9/0.0/<0.1 Levofloxacin 0.25 4 88.8/0.9/10.3 88.8/0.9/10.3 Erythromycin 0.25 >16 65.6/3.7/30.7 66.0/1.3/32.7 Clindamycin ≤0.25 ≤0.25 95.2/0.1/4.7 94.8/0.4/4.8 Gentamicin ≤1 ≤1 99.2/0.2/0.6 99.0/0.0/1.0 Tetracycline ≤0.25 ≤0.25 96.2/0.7/3.1 95.3/0.2/4.5 Trimethoprim-sulfamethoxazole ≤0.5 ≤0.5 99.5/0.0/0.5 99.5/0.1/0.4 MRSA (4,651) Telavancin 0.03 0.06 100.0/-/- -/-/- 100.0/-/- Vancomycin 1 1 >99.9/<0.1/0.0 >99.9/0.0/<0.1 Daptomycin 0.25 0.5 >99.9/-/- >99.9/0.0/<0.1 Linezolid 1 1 99.9/0.0/0.1 99.9/0.0/0.1 Levofloxacin 4 >4 31.3/2.2/66.5 31.3/2.2/66.5 Erythromycin >16 >16 10.4/1.9/87.7 10.6/0.5/88.9 Clindamycin ≤0.25 >2 70.5/0.1/29.4 70.2/0.3/29.5 Gentamicin ≤1 ≤1 96.8/0.1/3.1 96.5/0.0/3.5 Tetracycline ≤0.25 1 94.9/0.4/4.7 92.6/2.0/5.4 Trimethoprim-sulfamethoxazole ≤0.5 ≤0.5 97.8/0.0/2.2 97.8/0.2/2.0 MRSA with vancomycin MIC 2–4 μg/ml (4,651) Telavancin 0.06 0.06 100.0/-/- -/-/- 100.0/-/- Vancomycin 2 2 98.9/1.1/0.0 98.9/0.0/1.1 Daptomycin 0.5 1 97.8/-/- 97.8/0.0/2.2 Linezolid 1 2 98.9/0.0/1.1 98.9/0.0/1.1 Levofloxacin >4 >4 14.4/0.0/85.6 14.4/0.0/85.6 Erythromycin >16 >16 5.6/1.1/93.3 5.6/1.1/93.3 Clindamycin >2 >2 36.7/0.0/63.3 36.7/0.0/63.3 Gentamicin ≤1 2 91.1/0.0/8.9 88.9/0.0/11.1 Tetracycline ≤0.25 2 95.6/1.1/3.3 88.9/6.7/4.4 Trimethoprim-sulfamethoxazole ≤0.5 ≤0.5 97.8/0.0/2.2 97.8/1.1/1.1 MDR MRSA (1,371) Telavancin 0.03 0.06 100.0/-/- -/-/- 100.0/-/- Vancomycin 1 1 99.9/0.1/0.0 99.9/0.0/0.1 Daptomycin 0.25 0.5 99.9/-/- 99.9/0.0/0.1 Linezolid 1 1 99.7/0.0/0.3 99.7/0.0/0.3 Levofloxacin >4 >4 0.9/0.3/98.8 0.9/0.3/98.8 Erythromycin >16 >16 0.5/0.4/99.1 0.5/0.1/99.4 Clindamycin >2 >2 6.3/0.0/93.7 6.3/0.0/93.7 Gentamicin ≤1 4 90.2/0.2/9.6 89.9/0.0/10.1 Tetracycline ≤0.25 >8 88.6/0.2/11.2 82.4/6.1/11.5 Trimethoprim-sulfamethoxazole ≤0.5 ≤0.5 93.9/0.0/6.1 93.9/0.7/5.4 ↵a MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus; MDR, multidrug resistant.
↵b Telavancin breakpoint criteria for S. aureus according to the labeling supplement for the product (Vibativ) and EUCAST (MRSA only) at ≤0.12 μg/ml for susceptibility.
↵c -, breakpoint not available.
